Akums Drugs and Pharmaceuticals Limited (AKUMS) — Offer Document | 10 August 2026

10 August 2026 · NSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

CRISIL Monitoring Agency Report confirms full IPO proceeds utilization by Akums Drugs and Pharmaceuticals Limited for the quarter ended June 30, 2026.

🔄 What Changed

Rs 6,421.80 million fully deployed across debt repayment, subsidiary loans, working capital, acquisitions, and general corporate purposes with no deviations.

🔮 What's Next

No forward guidance provided in the filing.

💡 Investor Takeaway

All IPO funds were deployed as planned with no unused proceeds remaining.

CRISIL Ratings' August 10, 2026 monitoring report confirms Akums Drugs and Pharmaceuticals Limited fully utilized IPO proceeds of Rs 6,421.80 million by June 30, 2026, for debt repayment, subsidiary loan clearance, working capital, inorganic growth, and general corporate purposes, with no deviations or delays in implementation.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AKUMS ✨ Ask AI About This

About Akums Drugs and Pharmaceuticals Limited (AKUMS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹12,594.67 CrP/E: 42.0ROE: 8.8%ROCE: 15.4%Div Yield: 0.37%

View full AKUMS stock details →

📡 Get AI alerts when AKUMS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AKUMS — Free

💡 Ask AI about this filing

"What is the current debt-to-equity ratio after IPO proceeds deployment?""How does the Rs 301.80 million acquisition delay impact future inorganic growth plans?""What is the expected return on investment for the general corporate purpose funds utilized?"

Ask AI Free →

📊 More AKUMS filings

Announcement — 25 September 2026Akums Drugs & Pharmaceuticals announced that its insider trading compliance window closes on October...
🔴 Announcement — 23 September 2026Akums Drugs & Pharmaceuticals announced its schedule for two institutional investor meetings on Sept...
🔴 Announcement — 16 September 2026Akums Drugs & Pharmaceuticals announced its participation in a scheduled investor and analyst meet o...
🔴 Announcement — 3 September 2026Akums Drugs & Pharmaceuticals announced it received an ESG rating of 65 from NSE Sustainability for ...
Announcement — 25 August 2026Akums Drugs and Pharmaceuticals announced its participation in scheduled investor and analyst meetin...

See all AKUMS filings →

🔥 Also filed on 10 August 2026

TIMKENTimken India LimitedFinancial Results DOMSDOMS Industries LimitedCorporate Action HGSHinduja Global Solutions LimitedFinancial Results SUNDRMFASTSundram Fasteners LimitedFinancial Results AMJLANDAmj Land Holdings LimitedAnnual Report KANSAINERKansai Nerolac Paints LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AKUMS files new disclosures

Track AKUMS filings, board meetings, and corporate actions. Free email alerts at 5 PM.